The ASSESS-AKI Study found urinary epidermal growth factor is associated with reduced risk of major adverse kidney events

MLA

Menez, Steven, et al. “The ASSESS-AKI Study Found Urinary Epidermal Growth Factor Is Associated with Reduced Risk of Major Adverse Kidney Events.” Kidney International, vol. 104, no. 6, Dec. 2023, pp. 1194–205. EBSCOhost, https://doi.org/10.1016/j.kint.2023.08.007.

APA

Menez, S., Wen, Y., Xu, L., Moledina, D. G., Thiessen-Philbrook, H., Hu, D., Obeid, W., Bhatraju, P. K., Ikizler, T. A., Siew, E. D., Chinchilli, V. M., Garg, A. X., Go, A. S., Liu, K. D., Kaufman, J. S., Kimmel, P. L., Himmelfarb, J., Coca, S. G., Cantley, L. G., & Parikh, C. R. (2023). The ASSESS-AKI Study found urinary epidermal growth factor is associated with reduced risk of major adverse kidney events. Kidney International, 104(6), 1194–1205. https://doi.org/10.1016/j.kint.2023.08.007

Chicago

Menez, Steven, Yumeng Wen, Leyuan Xu, Dennis G. Moledina, Heather Thiessen-Philbrook, David Hu, Wassim Obeid, et al. 2023. “The ASSESS-AKI Study Found Urinary Epidermal Growth Factor Is Associated with Reduced Risk of Major Adverse Kidney Events.” Kidney International 104 (6): 1194–1205. doi:10.1016/j.kint.2023.08.007.